T1	Participants 1089 1216	one for patients with malignant disease (intervention delivered over two weeks) and one for patients with non-malignant disease
T2	Participants 1328 1434	patients with malignant conditions (four week protocol) and one for patients with non-malignant conditions
T3	Participants 1501 1509	patients
T4	Participants 1775 1782	patient
T5	Participants 234 242	patients
